These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7191300)

  • 1. [Studies on the possible correlations between in vitro and in vivo data using commercial triamterene formulations (author's transl)].
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1980; 30(7):1158-63. PubMed ID: 7191300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)].
    Knauf H; Mutschler E; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1417-20. PubMed ID: 582409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of triamterene and its metabolite in man.
    Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment in the elderly: special aspects of diuretics (author's transl)].
    Mühlberg W; Platt D
    Aktuelle Gerontol; 1982 Jul; 12(4):134-8. PubMed ID: 6126136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative studies on the in vitro dissolution and bioavailability of various acetylsalicylic acid preparations].
    Nieder M; Rasper J; Gielsdorf W; Russmann D; Jaeger H
    Arzneimittelforschung; 1983; 33(3):439-45. PubMed ID: 6683520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of triamterene.
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Clin Exp Hypertens A; 1983; 5(2):249-69. PubMed ID: 6831748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the determination of triamterene, hydroxythiamterene and hydroxytriamterene sulphate ester in biologica material by direct evaluation of thin-layer chromatograms (author's transl)].
    Grebian B; Geissler HE; Mutschler E
    Arzneimittelforschung; 1976; 26(12):2125-7. PubMed ID: 1037260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Triamterene induced nephrolithiasis (author's transl)].
    Lucas C; Cukier J; Daudon M; Protat MF; Reveillaud RJ
    J Urol (Paris); 1982; 88(1):37-42. PubMed ID: 7037980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
    Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
    J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution properties of different designed and formulated salbutamol tablet dosage forms.
    Ozkan Y; Savaşer A; Ozalp Y; Işimer A
    Acta Pol Pharm; 2000; 57(4):271-6. PubMed ID: 11126615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Klin Wochenschr; 1983 Sep; 61(18):883-91. PubMed ID: 6632729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug induced nephrolithiasis: observation of an oxalate and hydroxylated triamterene stone (author's transl)].
    Baudin S; Rodrigue H
    Nephrologie; 1980; 1(4):183-5. PubMed ID: 7301028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral triamterene disposition.
    Sörgel F; Hasegawa J; Lin ET; Williams RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):306-12. PubMed ID: 4028626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin.
    Ammar HO; Khalil RM
    Pharmazie; 1996 Mar; 51(3):165-8. PubMed ID: 8900866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.